New vaccines for the world's poorest people

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 405-417

  Hotez, Peter J ^a,b,c,d,e,f   Bottazzi, Maria Elena ^a,b,c,e,f   Strych, Ulrich ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Texas Children's Hospital Center for Vaccine Development ^*  (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d SABIN VACCINE INSTITUTE   (United States)

^e RICE UNIVERSITY   (United States)

^f BAYLOR UNIVERSITY   (United States)

Author keywords

Diseases of poverty; Global access; Neglected tropical diseases; Parasites; Product development partnerships

Indexed keywords

BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; PNEUMOCOCCUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; ROTAVIRUS VACCINE; VACCINE;

ARTICLE; CHAGAS DISEASE; CHILDHOOD DISEASE; DEVELOPING COUNTRY; DISABILITY; HOOKWORM INFECTION; HUMAN; LEISHMANIASIS; NON PROFIT ORGANIZATION; NONHUMAN; POVERTY; PRIORITY JOURNAL; SCHISTOSOMIASIS; TROPICAL DISEASE; VACCINE PRODUCTION; COOPERATION; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; HIV INFECTIONS; HOOKWORM INFECTIONS; MALARIA; MOTIVATION; NEGLECTED DISEASES; SUPPLY AND DISTRIBUTION; TUBERCULOSIS, PULMONARY; UNIVERSITY; WORLD HEALTH ORGANIZATION;

CHAGAS DISEASE; COOPERATIVE BEHAVIOR; DEVELOPING COUNTRIES; DRUG DISCOVERY; DRUG INDUSTRY; GOALS; HIV INFECTIONS; HOOKWORM INFECTIONS; HUMANS; LEISHMANIASIS; MALARIA; NEGLECTED DISEASES; ORGANIZATIONS, NONPROFIT; POVERTY; SCHISTOSOMIASIS; TUBERCULOSIS, PULMONARY; UNIVERSITIES; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84954529706     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051214-024241     Document Type: Article

References (81)

1. Sachs J. (2001). Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organ
2. GBD Mortality and Causes of Death Collab. (2015). Global, regional, and national age-sex specific allcause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385: 117-71
3. United Nations Development Programme. (2014). The Millennium Development Goals Report. http://www.undp.org/content/dam/undp/library/MDG/english/UNDP-MDGReport-EN-2014Final1.pdf
4. Hotez PJ, Herricks J. (2015). What kills little kids? PLOS Blog, Feb. 24. http://blogs.plos.org/speakingofmedicine/2015/02/24/kills-little-kids/
5. WHO.2015. Global vaccine action plan 2011-2020. http://www.who.int/immunization/global-vaccine-Action-plan/en/
6. WHO. (2012). Global vaccine action plan. http://www.who.int/immunization/global-vaccine-Action-plan/GVAP-Strategic-Objective-1-6.pdf
7. Murray CJ, Ortblad KF, Guinovart C, et al. (2014). Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384: 1005-70
8. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. (2013). New vaccines for neglected parasitic diseases and dengue. Transl. Res. J. Lab. Clin. Med. 162: 144-55
9. Breitstein J, Spigelman M. (2013). The role of product development partnerships in advancing the development of drugs for unmet needs. Clin. Pharmacol. Ther. 93: 468-70
10. Pratt B, Loff B. (2013). Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building. Am. J. Public Health 103: 1968-78
11. Deutsche Stiftung Weltbevölkerung (DSW). (2014). A healthier world: tackling neglected diseases. http://3kck0t38mmqdnrjfp23kzm9tz0.wpengine.netdna-cdn.com/wp-content/uploads/2014/06/DSWreport. pdf
12. Delany I, Rappuoli R, De Gregorio E. (2014). Vaccines for the 21st century. EMBO Mol. Med. 6: 708-20
13. RTS, S Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, et al. (2012). A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367: 2284-95
14. RTS, S Clinical Trials Partnership. (2014). Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11: e1001685
15. Haynes BF, Moody MA, Alam M, et al. (2014). Progress in HIV-1 vaccine development. J. Allergy Clin. Immunol. 134: 3-10
16. O'Ryan M, Vidal R, Del Canto F, et al. (2015). Vaccines for viral and bacterial pathogens causing acute gastroenteritis. Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Hum. Vaccines Immunotherapeut. 11: 584-600
17. Ivers LC, Hilaire IJ, Teng JE, et al. (2015). Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. Lancet Global Health 3: e162-68
18. Chen WH, Greenberg RN, Pasetti MF, et al. (2014). Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-Hg R, prepared from new master and working cell banks. Clin. Vaccine Immunol. 21: 66-73
19. Guvenel AK, Chiu C, Openshaw PJ. (2014). Current concepts and progress in RSV vaccine development. Expert Rev. Vaccines 13: 333-44
20. Tameris MD, Hatherill M, Landry BS, et al. (2013). Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-28
21. Kagina BM, Tameris MD, Geldenhuys H, et al. (2014). The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine 32: 5908-17
22. Molyneux DH, Hotez PJ, Fenwick A. (2005). Rapid-impact interventions: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2: e336
23. Hotez PJ (2013). Forgotten People, Forgotten Diseases The Neglected Tropical Diseases and Their Impact on Global Health and Development.Washington, DC: ASM Press
24. WHO. (2015). The 17 neglected tropical diseases. http://www.who.int/neglected-diseases/diseases/summary/en/
25. Hotez PJ, Alvarado M, Basanez MG, et al. (2014). The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Neglected Trop. Dis. 8: e2865
26. Hotez PJ, Ferris MT. (2006). The antipoverty vaccines. Vaccine 24: 5787-99
27. Hotez P, Whitham M. (2014). Helminth infections: a new global women's health agenda. Obstet. Gynecol. 123: 155-60
28. Hotez P. (2011). A handful of antipoverty vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff. 30: 1080-87
29. WHO. (2014). Product Development for Vaccines Advisory Committee (established April 2014). http://www.who.int/immunization/research/committees/pdvac/en/
30. Hotez PJ, Pecoul B, Rijal S, et al. (2015). Eliminating the neglected tropical diseases translational science and new technologies. PLoS Neglected Trop. Dis. In press
31. Bethony JM, Cole RN, Guo X, et al. (2011). Vaccines to combat the neglected tropical diseases. Immunol. Rev. 239: 237-70
32. Bottazzi ME, Brown AS. (2008). Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. Expert Rev. Vaccines 7: 1481-92
33. Bottazzi ME, Miles AP, Diemert D, Hotez PJ. (2006). An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev. Vaccines 5: 189-98
34. Serruto D, Bottomley MJ, Ram S, et al. (2012). The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(Suppl. 2): B87-97
35. Seib KL, Zhao X, Rappuoli R. (2012). Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin. Microbiol. Infect. 18(Suppl. 5): 109-16
36. Bethony JM, Periago MV, Jariwala A. (2012). Barefoot thru' the Valley ofDarkness: preclinical development of the human hookworm vaccine. In ParasiticHelminths: Targets, Screens, Drugs andVaccines, ed.CRCaffrey, pp. 343-56. Weinheim, Ger.: Wiley-VCH
37. Giersing BK, Dubovsky F, Saul A, et al. (2006). Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 24: 4264-70
38. Seid CA, Curti E, Jones RM, et al. (2015). Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum. Vaccines Immunotherapeut. 11: 1474-88
39. Goud GN, Deumic V, Gupta R, et al. (2012). Expression, purification, andmolecular analysis of the Necator americanus glutathione S-Transferase 1 (Na-GST-1): a production process developed for a lead candidate recombinant hookworm vaccine antigen. Protein Expr. Purif. 83: 145-51
40. Curti E, Kwityn C, Zhan B, et al. (2013). Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum. Vaccines Immunotherapeut. 9: 2342-50
41. Legrand N, Ploss A, Balling R, et al. (2009). Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6: 5-9
42. Siu E, Ploss A. (2015). Modeling malaria in humanized mice: opportunities and challenges. Ann. N.Y. Acad. Sci. 1342: 29-36
43. Kaushansky A, Mikolajczak SA, Vignali M, Kappe SH. (2014). Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections. Cell Microbiol. 16: 602-11
44. Diemert DJ, Pinto AG, Freire J, et al. (2012). Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. J. Allergy Clin. Immunol. 130: 169-76
45. Hotez PJ, Bethony JM, Diemert DJ, et al. (2010). Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 8: 814-26
46. Alexander N, Cundill B, Sabatelli L, et al. (2011). Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. Vaccine 29: 3686-94
47. Spring M, Polhemus M, Ockenhouse C. (2014). Controlled human malaria infection. J. Infect. Dis. 209(Suppl. 2): S40-45
48. ClinicalTrials.gov. (2014). Experimental infection of hookworm-naïve adults with dermally-Applied infectious Necator americanus hookworm larvae. https://clinicaltrials.gov/ct2/show/NCT01940757
49. Bottazzi ME. (2014). Vaccines against neglected tropical diseases: promising interventions to rescue the poorest populations in the Americas. Immunotherapy 6: 117-19
50. Mgone CS, Salami W. (2009). EDCTP: a genuine north-south partnership. Trop.Med. Int.Health 14: 1327-28
51. Matee MI, Manyando C, Ndumbe PM, et al. (2009). European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership. BMC Public Health 9: 249
52. Zumla A, Makanga M, Nyirenda T, et al. (2015). Genesis of EDCTP2. Lancet Infect. Dis. 15: 11-13
53. Hotez PJ. (2013). NTDs V.2.0: blue marble health-neglected tropical disease control and elimination in a shifting health policy landscape. PLoS Neglected Trop. Dis. 7: e2570
54. Wade K. (2013). Confronting neglected tropical diseases: Will highly endemic countries buy in? D Blog, Dec. 20. http://dalberg.com/blog/?p=2372
55. GAVI. (2015). Pneumococcal AMC. http://www.gavi.org/funding/pneumococcal-Amc/
56. Ridley DB, Sanchez AC. (2010). Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet 376: 922-27
57. Ridley DB, Grabowski HG, Moe JL. (2006). Developing drugs for developing countries. Health Aff. 25: 313-24
58. Food and Drug Administration (FDA). (2008). Guidance for industry: tropical disease priority review vouchers. http://www.fda.gov/downloads/Drugs/Guidances/UCM080599.pdf
59. Gaffney A, Mezher M. (2015). Regulatory explainer everything you need to know about FDA's priority review vouchers. Regulatory Focus, July 2
60. Stefanakis R, Robertson AS, Ponder EL, Moree M. (2012). Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade. PLoS Neglected Trop. Dis. 6: e1803
61. Slingsby BT, Kurokawa K. (2013). The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations. Lancet Global Health 1: e184-85
62. Moran M, Guzman J, Ropars AL, Illmer A. (2010). The role of Product Development Partnerships in research and development for neglected diseases. Int. Health 2: 114-22
63. Global Health Investment Fund (GHIF). (2014). GHIF leads US$7.5m investment into EuBiologics. http://www.lhgp.com/ghif-leads-us7-5m-investment-into-eubiologics/
64. ClinicalTrials.gov. (2015). Safety and immunogenicity study of Na-GST-1 with or without Cp G. https://clinicaltrials.gov/ct2/show/NCT02143518
65. ClinicalTrials.gov. (2015). Safety and immunogenicity of the Na-APR-1 hookworm vaccine in healthy adults. https://clinicaltrials.gov/ct2/show/NCT01717950
66. ClinicalTrials.gov. (2015). Safety and immunogenicity of co-Administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults. https://clinicaltrials.gov/ct2/show/NCT02126462
67. ClinicalTrials.gov. (2015). Study of Na-APR-1 (M74)/Alhydrogel R-co-Administered with Na-GST-1/Alhydrogel in Brazilian adults. https://clinicaltrials.gov/ct2/show/NCT02476773
68. ClinicalTrials.gov. (2011). Safety and immunogenicity of a human hookworm candidate vaccine with different doses of a novel adjuvant. https://clinicaltrials.gov/ct2/show/NCT01385189
69. ClinicalTrials.gov. (2012). Efficacy of vaccine Sh28GST in association with praziquantel (PZQ) for prevention of clinical recurrences of Schistosoma haematobium pathology (Bilhvax). https://clinicaltrials.gov/ct2/show/NCT00870649
70. ClinicalTrials.gov. (2015). A Phase I study of the safety, reactogenicity, and immunogenicity of Sm-TSP-2/Alhydrogel R-with or without GLA-AF for intestinal schistosomiasis in healthy adults. https://clinicaltrials. gov/ct2/show/NCT02337855
71. ClinicalTrials.gov. (2015). Study to evaluate the safety of the vaccine prepared sm14 against schistosomiasis. https://clinicaltrials.gov/ct2/show/NCT01154049
72. ClinicalTrials.gov. (2014). Phase 1 LEISH-F3 + SLA-SE vaccine trial in healthy adult volunteers. https://clinicaltrials.gov/ct2/show/NCT02071758
73. ClinicalTrials.gov. (2011). Study of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia. https://clinicaltrials.gov/ct2/show/NCT01373281
74. ClinicalTrials.gov. (2011). Study of a novel tetravalent dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America. https://clinicaltrials.gov/ct2/show/NCT01374516
75. ClinicalTrials.gov. (2009). Study of Sanofi Pasteur's CYD dengue vaccine in healthy subjects in Singapore. https://clinicaltrials.gov/ct2/show/NCT00880893
76. ClinicalTrials.gov. (2012). Phase II trial to evaluate safety and immunogenicity of a dengue 1, 2, 3, 4 (attenuated) vaccine. https://clinicaltrials.gov/ct2/show/NCT01696422
77. ClinicalTrials.gov. (2015). Evaluating the safety and protective efficacy of a single dose of a trivalent live attenuated dengue vaccine to protect against infection with DENV-2. https://clinicaltrials.gov/ct2/show/NCT02433652
78. ClinicalTrials.gov. (2014). TDENV PIV and LAV dengue prime-boost strategy. https://clinicaltrials.gov/ct2/show/NCT02239614
79. ClinicalTrials.gov. (2015). Phase III trial to evaluate efficacy and safety of a tetravalent dengue vaccine. https://clinicaltrials.gov/ct2/show/NCT02406729
80. ClinicalTrials.gov. (2014). Safety and immunogenicity of different schedules of Takeda's tetravalent dengue vaccine candidate (TDV) in healthy participants. https://clinicaltrials.gov/ct2/show/NCT02302066
81. ClinicalTrials.gov. (2015). Safety and immunogenicity with two different serotype 2 potencies of tetravalent dengue vaccine (TDV) in adults in Singapore. https://clinicaltrials.gov/ct2/show/NCT02425098 www